Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 8256 participants.

Also called NCT02929329

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 8,256 participants (enrolled count) (from the registry)
Sponsor
  • Cytokinetics Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02929329
  • EudraCT 2016-002299-28
Other papers using this trial's data
  • Assessment of Omecamtiv Mecarbil for the Treatment of Patients With Severe Heart Failure: A Post Hoc Analysis of Data From the GALACTIC-HF Randomized Clinical Trial JAMA cardiology, 2022-01-01 DOI, PubMed 34643642, PMC8515258 Not in the PMC Open Access subset.
  • Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure The New England journal of medicine, 2021-01-14 DOI, PubMed 33185990
  • Cardiac Troponin and Treatment Effects of Omecamtiv Mecarbil: Results From the GALACTIC-HF Study Journal of cardiac failure, 2024-06 DOI, PubMed 38215932
  • Dipstick proteinuria and outcomes in patients with heart failure and reduced ejection fraction: insights from GALACTIC-HF European journal of heart failure, 2026-05-11 DOI, PubMed 41771088
  • Efficacy and Safety of Omecamtiv Mecarbil in Heart Failure With Reduced Ejection Fraction According to Age: The GALACTIC-HF Trial JACC. Heart failure, 2026-02 DOI, PubMed 41123512
  • Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide level: insights from the GALACTIC-HF trial European journal of heart failure, 2023-02 DOI, PubMed 36597719
  • Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial European heart journal, 2022-06-14 DOI, PubMed 35325102 PubMed links an erratum for this paper. Erratum: PMID 35715934
  • Lactate Dehydrogenase and Outcomes in Patients With HF and Reduced Ejection Fraction: Insights From GALACTIC-HF JACC. Heart failure, 2026-05 DOI, PubMed 41528277
  • Sex Differences in Heart Failure With Reduced Ejection Fraction in the GALACTIC-HF Trial JACC. Heart failure, 2023-12 DOI, PubMed 37831045

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Czechia, Denmark, France, Germany, Greece, Hungary, Italy, Japan, Lithuania, Mexico, Netherlands, New Zealand, Poland, Portugal, Puerto Rico, Romania, Russia, Slovakia, South Africa, Spain, Sweden, Switzerland, Türkiye, Ukraine, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02929329. Randomized; triple masking; primary purpose treatment. Start 2017-01-06 (actual); primary completion 2020-09-14 (actual). Results posted on 2021-07-20.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction
Acronym
GALACTIC-HF
Condition
Heart Failure
Intervention (Drug)
Omecamtiv Mecarbil
Intervention (Drug)
Placebo
Intervention (Drug)
Standard of Care
Lead sponsor
Cytokinetics (class: industry)

Record details

Record id
cardio:ct-nct02929329
Content hash
1f3567d36fed402a428692fde6c9e192428591ddf37e8e1c011398c7e28755e6